(Total Views: 424)
Posted On: 02/10/2018 10:27:10 PM
Post# of 72441
BIVV is a spin off of the hemophilia research wing from Biogen.
https://www.bioverativ.com/research-pipeline/...eline.aspx
The only thing they have is TNT009 which was acquired for $825M purchased by them in 2017.
Had a $6B market cap prior to the buyout. Not bad turning a sub-IPIX pipeline purchased for $825M into $11B+.
Go IPIX!
https://www.bioverativ.com/research-pipeline/...eline.aspx
The only thing they have is TNT009 which was acquired for $825M purchased by them in 2017.
Had a $6B market cap prior to the buyout. Not bad turning a sub-IPIX pipeline purchased for $825M into $11B+.
Go IPIX!
(0)
(0)
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
Scroll down for more posts ▼
